Human Gingiva-Derived Mesenchymal Stem Cells Ameliorate Streptozoticin-induced T1DM in Mice Via Suppression of T Effector Cells and Up-regulating Treg Subsets

Overview

Journal Sci Rep

Specialty Science

Date 2017 Nov 12

PMID 29127315

Citations 39

Authors

Wei Zhang

Li Zhou

Junlong Dang

Ximei Zhang

Julie Wang

Yanming Chen

Jichao Liang

Dongqing Li

Jilin Ma

Jia Yuan

Weiwen Chen

Homayoun H Zadeh

Nancy Olsen

Song Guo Zheng

Affiliations

Soon will be listed here.

Abstract

There is yet no cure for type 1 diabetes (T1DM) so far. A significant body of evidence has demonstrated that bone marrow-derived mesenchymal stem cells (BMSCs) showed great potential in controlling T1DM. But there exists much difficulty in using BMSCs as a clinical therapy. We here test whether a new population of mesenchymal stem cells from human gingiva (GMSCs), which has many advantages over BMSCs, can delay or prevent progress of T1DM. GMSCs were adoptively transferred to multiple low-dose streptozotocin (STZ)-induced T1DM. Blood glucose levels and disease severities were analyzed. T cells subsets in blood, spleen and lymph nodes were detected dynamically by flow cytometry. GMSC distribution was dynamically analyzed. We found that infusion of GMSCs but not fibroblast cells significantly controlled blood glucose levels, delayed diabetes onset, ameliorated pathology scores in pancreas, and down-regulated production of IL-17 and IFN-γ in CD4 and CD8 T cells in spleens, pancreatic lymph nodes (pLN) and other lymph nodes. GMSCs also up-regulated the levels of CD4 Treg induced in the periphery. Mechanismly, GMSCs could migrate to pancreas and local lymph node and function through CD39/CD73 pathway to regulate effector T cells. Thus, GMSCs show a potential promise in treating T1DM in the clinic.

Citing Articles

CD73: agent development potential and its application in diabetes and atherosclerosis.

Liu D, Zhao J, Li L, Wang J, Wang C, Wu Y Front Immunol. 2024; 15:1515875.

PMID: 39735551 PMC: 11672340. DOI: 10.3389/fimmu.2024.1515875.

Gingival Mesenchymal Stem Cells: A Periodontal Regenerative Substitute.

Shetty S, Sowmya S, Pradeep A, Jayakumar R Tissue Eng Regen Med. 2024; 22(1):1-21.

PMID: 39607668 PMC: 11711796. DOI: 10.1007/s13770-024-00676-8.

Dental stem cell dynamics in periodontal ligament regeneration: from mechanism to application.

Wen S, Zheng X, Yin W, Liu Y, Wang R, Zhao Y Stem Cell Res Ther. 2024; 15(1):389.

PMID: 39482701 PMC: 11526537. DOI: 10.1186/s13287-024-04003-9.

Mesenchymal Stem/Stromal Cells Derived from Dental Tissues Mediate the Immunoregulation of T Cells through the Purinergic Pathway.

Poblano-Perez L, Monroy-Garcia A, Fragoso-Gonzalez G, Mora-Garcia M, Castell-Rodriguez A, Mayani H Int J Mol Sci. 2024; 25(17).

PMID: 39273524 PMC: 11395442. DOI: 10.3390/ijms25179578.

Gingival mesenchymal stem cells: Biological properties and therapeutic applications.

Peng Y, Jaar J, Tran S J Oral Biol Craniofac Res. 2024; 14(5):547-569.

PMID: 39108352 PMC: 11301388. DOI: 10.1016/j.jobcr.2024.07.003.

References

Emamaullee J, Davis J, Merani S, Toso C, Elliott J, Thiesen A . Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes. 2009; 58(6):1302-11. PMC: 2682686. DOI: 10.2337/db08-1113. View

Sohni A, Verfaillie C . Mesenchymal stem cells migration homing and tracking. Stem Cells Int. 2013; 2013:130763. PMC: 3806396. DOI: 10.1155/2013/130763. View

Lin M, Yin N, Murphy B, Medof M, Segerer S, Heeger P . Immune cell-derived c3 is required for autoimmune diabetes induced by multiple low doses of streptozotocin. Diabetes. 2010; 59(9):2247-52. PMC: 2927947. DOI: 10.2337/db10-0044. View

Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D . Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004; 103(12):4619-21. DOI: 10.1182/blood-2003-11-3909. View

Alberti K, Zimmet P . Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15(7):539-53. DOI: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S. View

Zhang Q, Su W, Shi S, Wilder-Smith P, Xiang A, Wong A . Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells. 2010; 28(10):1856-68. PMC: 3114043. DOI: 10.1002/stem.503. View

Redaelli S, Bentivegna A, Foudah D, Miloso M, Redondo J, Riva G . From cytogenomic to epigenomic profiles: monitoring the biologic behavior of in vitro cultured human bone marrow mesenchymal stem cells. Stem Cell Res Ther. 2012; 3(6):47. PMC: 3580477. DOI: 10.1186/scrt138. View

Thornton A, Korty P, Tran D, Wohlfert E, Murray P, Belkaid Y . Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol. 2010; 184(7):3433-41. PMC: 3725574. DOI: 10.4049/jimmunol.0904028. View

Yadav M, Louvet C, Davini D, Gardner J, Martinez-Llordella M, Bailey-Bucktrout S . Neuropilin-1 distinguishes natural and inducible regulatory T cells among regulatory T cell subsets in vivo. J Exp Med. 2012; 209(10):1713-22, S1-19. PMC: 3457729. DOI: 10.1084/jem.20120822. View

10.

Ueda Yaochite J, Caliari-Oliveira C, Davanso M, Carlos D, Malmegrim K, de Barros Cardoso C . Dynamic changes of the Th17/Tc17 and regulatory T cell populations interfere in the experimental autoimmune diabetes pathogenesis. Immunobiology. 2012; 218(3):338-52. DOI: 10.1016/j.imbio.2012.05.010. View

11.

Rewers M, Gottlieb P . Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabetes Care. 2009; 32(10):1769-82. PMC: 2752911. DOI: 10.2337/dc09-0374. View

12.

Ryba-Stanislawowska M, Skrzypkowska M, Mysliwiec M, Mysliwska J . Loss of the balance between CD4(+)Foxp3(+) regulatory T cells and CD4(+)IL17A(+) Th17 cells in patients with type 1 diabetes. Hum Immunol. 2013; 74(6):701-7. DOI: 10.1016/j.humimm.2013.01.024. View

13.

Liu S, Tsai J, Shen C, Sher Y, Hsieh C, Yeh Y . Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6. J Leukoc Biol. 2007; 82(2):354-60. DOI: 10.1189/jlb.0207111. View

14.

Katz J, Benoist C, Mathis D . T helper cell subsets in insulin-dependent diabetes. Science. 1995; 268(5214):1185-8. DOI: 10.1126/science.7761837. View

15.

Ferraro A, Socci C, Stabilini A, Valle A, Monti P, Piemonti L . Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes. 2011; 60(11):2903-13. PMC: 3198077. DOI: 10.2337/db11-0090. View

16.

Shao S, He F, Yang Y, Yuan G, Zhang M, Yu X . Th17 cells in type 1 diabetes. Cell Immunol. 2012; 280(1):16-21. DOI: 10.1016/j.cellimm.2012.11.001. View

17.

Carlsson P, Schwarcz E, Korsgren O, Le Blanc K . Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes. 2014; 64(2):587-92. DOI: 10.2337/db14-0656. View

18.

Oehen S, Oxenius A, Odermatt B . A simple method for evaluating the rejection of grafted spleen cells by flow cytometry and tracing adoptively transferred cells by light microscopy. J Immunol Methods. 1997; 207(1):33-42. DOI: 10.1016/s0022-1759(97)00089-6. View

19.

Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M . Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004; 363(9419):1439-41. DOI: 10.1016/S0140-6736(04)16104-7. View

20.

Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E . IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008; 38(6):1745-55. PMC: 3021120. DOI: 10.1002/eji.200738129. View